Kanapka LG, Wadwa RP, Breton MD, et al. - The safety and efficacy of the Control-IQ closed-loop control (CLC) system was further examined in children with type 1 diabetes. After a 16-week randomized clinical trial (RCT) comparing CLC with sensor-augmented pump (SAP) therapy in 101 children age 6–13 years old with type 1 diabetes, CLC system use was initiated by 22 participants in the SAP group (referred to as SAP-CLC cohort), and its use was continued in 78 participants in the CLC group (CLC-CLC cohort) for 12 weeks. Supporting the findings of the preceding RCT, this further evaluation of the Control-IQ CLC system suggested that in children 6–13 years old with type 1 diabetes, use of a closed-loop system can safely improve glycemic control from the 1st day of use and demonstrate that these improvements can be through 28 weeks of use.